eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
04/01/21
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
03/25/21
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
03/23/21
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Upcoming Events
There are currently no events scheduled.